Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Genahead Bio Inc. is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 1 distinct examiner, DEBERRY, REGINA M, within 1 distinct art unit. This concentration suggests that the company's current filings are being reviewed by the same individual, providing a consistent point of contact for their Biotechnology & Pharmaceuticals work. The presence of 2 pending office actions indicates an active prosecution phase within a very focused technical scope.
DEBERRY, REGINA M is the busiest examiner for the portfolio, holding both of the 2 pending office actions. Because there is only 1 distinct examiner and 1 distinct art unit, the company's prosecution strategy is highly centralized. The outcome of these 2 pending actions will be heavily influenced by the specific requirements and feedback of this single examiner. This arrangement allows the company to apply insights gained from one action directly to the other, as both are handled by DEBERRY, REGINA M. However, it also means that the company's success in the Biotechnology & Pharmaceuticals sector is currently tied to the decisions of one person within a single art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DEBERRY, REGINA M | 2 | 50.1% | +30.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18637050 | ANTIBODY-DRUG CONJUGATE | DEBERRY, REGINA M | 19d overdue |
| 16311464 | ANTIBODY-DRUG CONJUGATE | DEBERRY, REGINA M | — |
| Art Unit | Apps |
|---|---|
| 1647 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18637050 | ANTIBODY-DRUG CONJUGATE | DEBERRY, REGINA M | 1647 | §112 | Final Rejection | 19d overdue | Pending | Apr 16, 2024 |
| 16311464 | ANTIBODY-DRUG CONJUGATE | DEBERRY, REGINA M | 1647 | §103 | Final Rejection | — | Pending | Feb 14, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial